Function and inhibition of Haspin kinase: targeting multiple cancer therapies by antimitosis

J Pharm Pharmacol. 2023 Apr 7;75(4):445-465. doi: 10.1093/jpp/rgac080.

Abstract

Objectives: Haploid germ cell-specific nuclear protein kinase (Haspin) is a serine/threonine kinase as an atypical kinase, which is structurally distinct from conventional protein kinases.

Key findings: Functionally, Haspin is involved in important cell cycle progression, particularly in critical mitosis regulating centromeric sister chromatid cohesion during prophase and prometaphase, and subsequently ensuring proper chromosome alignment during metaphase and the normal chromosome segregation during anaphase. However, increasing evidence has demonstrated that Haspin is significantly upregulated in a variety of cancer cells in addition to normal proliferating somatic cells. Its knockdown or small molecule inhibition could prevent cancer cell growth and induce apoptosis by disrupting the regular mitotic progression. Given the specificity of its expressed tissues or cells and the uniqueness of its current known substrate, Haspin can be a promising target against cancer. Consequently, selective synthetic and natural inhibitors of Haspin have been widely developed to determine their inhibitory power for various cancer cells in vivo and in vitro.

Summary: Here our perspective includes a comprehensive review of the roles and structure of Haspin, its relatively potent and selective inhibitors and Haspin's preliminary studies in a variety of cancers.

Keywords: GSG2; Haspin; cancer; inhibitor; mitosis; protein kinases.

Publication types

  • Review

MeSH terms

  • Antimitotic Agents*
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Mitosis
  • Neoplasms* / drug therapy
  • Phosphorylation
  • Protein Serine-Threonine Kinases / metabolism

Substances

  • Antimitotic Agents
  • Intracellular Signaling Peptides and Proteins
  • Protein Serine-Threonine Kinases